VANCOUVER, Sept. 27 /PRNewswire/ - The Board of Directors of Perceptronix Medical Inc. (“Perceptronix”) is pleased to announce the appointment of Mr. Carl F. Roy to the position of President and CEO, effective September 25, 2006.
Mr. Roy comes to Perceptronix from Providence Health Care (“Providence”), where he was President and Chief Executive Officer from May 2001 to September 2006. During his tenure at Providence, Mr. Roy strengthened and developed strategic alliances with Vancouver Coastal Health and the Provincial Health Services Authority. Prior to joining Providence, Mr. Roy was President of Caritas Health Group in Edmonton and previously, President and Chief Executive Officer of Sudbury General Hospital and St. Joseph’s Health Centre in Sudbury, Ontario. Mr. Roy has a Master of Health Science, Administration from the University of Toronto and is a Certified Health Executive (Canadian College of Health Service Executives).
Perceptronix will benefit from Mr. Roy’s demonstrated management skills in strategic planning and in developing innovative business models, his sound financial management skills and his ability to focus on priorities and to deliver results. Mr. Roy’s knowledge of front-line patient care will also be of immense strategic value in enabling the company to make its technologies and services widely available to patients.
Board Chairman, Milton Wong, stated that, “To be able to attract an executive of Mr. Roy’s calibre as the next leader for Perceptronix speaks to the company’s commercial potential and tremendous opportunity to improve patient outcomes through its diagnostic product portfolio. Carl brings strong leadership skills and a vision for healthcare that is closely aligned with the goals of the company.”
Perceptronix’s mission is the worldwide commercialization of effective, clinically relevant services and technologies for the earlier diagnosis of cancer. The company’s initial focus is on a portfolio of complementary diagnostic products to improve lung cancer outcomes.
“I’m excited by the great opportunities and challenges that my new role presents, especially knowing how Perceptronix’s technologies have the possibility of making a real, positive difference in people’s lives,” said Mr. Roy. “I am confident that my health care experience will be invaluable for achieving successful commercialization of Perceptronix’s breakthrough technologies, facilitating strategic collaborations, and enabling the company to meet its future milestones.”
About Perceptronix’s suite of technologies
Perceptronix’s suite of technologies and laboratory services is designed to approach cancer diagnosis comprehensively through early detection, localization, diagnosis and follow-up. The first of Perceptronix’s technologies to receive regulatory approvals are:
- ClearSign(TM) Sputum Test - This test is used for early lung cancer detection. ClearSign(TM) has a Health Canada license and CE Mark; - ClearCyte(TM) Test - This test is used to measure “gross genomic aberrations” (DNA Ploidy) to assist physicians with clinical diagnosis and prognosis of cancer. ClearCyte(TM) has a Health Canada license and CE Mark; - The Clear2C(TM) Quantitative DNA Staining Kit has a Health Canada license, CE Mark and US Food & Drug Administration Medical Device listing.
In development are ClearVu(TM) and ClearVu(TM) Elite, simultaneous and spectral fluorescence/white light endoscopy systems for cancer localization, and ClearPath(TM), an aid to definitive diagnosis of biopsy sections.
The Perceptronix Clinical Quantitative Cytology Laboratory in Vancouver, Canada, currently performs the ClearCyte(TM) Test to assist clinicians in the diagnosis and prognosis of cancer and expects to perform the ClearSign(TM) Sputum Test starting in Q4, 2006. This Laboratory operates under guidance from the Diagnostic Accreditation Program of the British Columbia College of Physicians and Surgeons and accreditation is expected to be achieved by year end.
About Perceptronix Medical Inc. (www.perceptronix.com)
Perceptronix is a private cancer diagnostics company based in Vancouver, Canada. Perceptronix commercializes early cancer detection technologies developed in partnership with the BC Cancer Agency (www.bccancer.bc.ca), a world-leader in cancer care and research and a pioneer in early cancer detection programs.
This news release is not, and under no circumstances is to be construed as, an advertisement, solicitation or offering of securities of Perceptronix Medical Inc. The statements made in this news release may contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company’s expectations.
CONTACT: Susan Grose, Corporate Secretary, Perceptronix Medical Inc., Phone: (604) 707-9037, info@perceptronix.com; Media Contact: Don Bradley, James Hoggan & Associates Inc., Phone: (604) 739-7500, Mobile: (604) 961-3883, dbradley@hoggan.com
Perceptronix Medical Inc.
CONTACT: Susan Grose, Corporate Secretary, Perceptronix Medical Inc.,Phone: (604) 707-9037, info@perceptronix.com; Media Contact: Don Bradley,James Hoggan & Associates Inc., Phone: (604) 739-7500, Mobile: (604)961-3883, dbradley@hoggan.com
